Abstract
Background. The purpose of this study was to retrospectively evaluate technetium 99m tetrofosmin
(Tc-TF) uptake in parathyroid adenomas and compare the results with their expression
of multidrug resistance-mediated 170-kDa P-glycoprotein (Pgp). Methods. Twenty patients with larger parathyroid adenomas (> 1.5 g) and the other 40 patients
with smaller parathyroid adenomas (0.5-1.5 g) underwent early and delayed (10-minute
and 2-hour) Tc-TF parathyroid imaging before operation. In this retrospective study,
immunohistochemical analyses were performed on multiple nonconsecutive sections of
the 40 parathyroid adenomas and 40 normal control specimens (20 normal parathyroid
glands and 20 normal thyroid specimens) to detect Pgp expression. Results. The Tc-TF parathyroid image accurately localized 17 larger and 16 smaller parathyroid
adenomas, but not the remaining 3 larger and 4 smaller adenomas. The 17 larger and
16 smaller parathyroid adenomas with significant Tc-TF uptake on the delayed 2-hour
parathyroid images revealed negative Pgp expression, but the 3 larger and 4 smaller
adenomas without significant Tc-TF uptake, as well as 20 normal parathyroid glands
and 20 normal thyroid specimens, revealed positive Pgp expression. Conclusions. Not only the size of parathyroid adenomas, but Pgp expression also limited the sensitivity
of Tc-TF parathyroid image to localize parathyroid adenomas before the operation.
(Surgery 2002;132:456-60.)
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Parathyroid imaging.Nucl Med Commun. 1995; 16: 522-533
- Parathyroid imaging.J Nucl Med. 1991; 32: 887-889
- Localization of parathyroid adenomas in patients who have undergone surgery. Part I. Noninvasive imaging methods.Radiology. 1987; 162: 133-137
- Procedure guideline for parathyroid scintigraphy. Society of Nuclear Medicine.J Nucl Med. 1998; 39: 1111-1114
- Simultaneous technetium-99m MIBI angiography and myocardial perfusion imaging.J Nucl Med. 1989; 30: 38-44
- Parathyroid imaging with technetium-99m sestamibi: preoperative localization and tissue uptake studies.J Nucl Med. 1992; 33: 313-318
- Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m sestamibi (double-phase study).J Nucl Med. 1992; 33: 1801-1807
- Technetium-99m-1,2-bis[bis(2-ethoxyethyl)phosphino]ethane: human biodistribution, dosimetry, and safety of a new myocardial perfusion imaging agent.J Nucl Med. 1993; 34: 30-38
- Technetium-99m tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging.J Nucl Med. 1993; 34: 222-227
- Technetium-99m tetrofosmin for parathyroid scintigraphy: a comparison with sestamibi.J Nucl Med. 1997; 38: 834
- Comparison of technetium-99m MIBI, technetium-99m tetrofosmin, ultrasound, and MRI for localization of abnormal parathyroid glands.J Nucl Med. 1998; 39: 320-324
- Parathyroid adenomas without sestamibi retention.Clin Nucl Med. 1995; 20: 699-702
- Comparison of Tc-99m MIBI and TI-201/Tc-99m pertechnetate for diagnosis of primary hyperparathyroidism.Clin Nucl Med. 1996; 21: 602-608
- Technetium-99m tetrofosmin scintigraphy, P-glycoprotein, and lung cancer.J Nucl Med. 1998; 39: 1830-1831
- Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein.J Nucl Med. 1998; 39: 77-86
- Pharmacokinetic modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates.Q J Nucl Med. 1997; 41: 101-110
- Visualization of multidrug resistance in vivo.Eur J Nucl Med. 1999; 26: 283-293
- Correlation between 99m Tc-tetrofosmin uptake and P-glycoprotein expression in non-small-cell lung cancer.Rev Esp Med Nucl. 1998; 17: 427-434
- Functional imaging of multidrug resistant P-glycoprotein with an organotechnetium complex.Cancer Res. 1993; 53: 977-984
- Expression of recombinant human multidrug-resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m sestamibi.J Nucl Med. 1994; 35: 510-515
- Association of tumor washout rates and accumulation of technetium-99m MIBI with expression of P-glycoprotein in lung cancer.J Nucl Med. 1998; 39: 228-234
- Correlation between P-glycoprotein (Pgp) expression in parathyroid and Tc-99m MIBI parathyroid image findings.Nucl Med Biol. 2001; 28: 929-933
- MDR1 gene expression in primary and advanced breast cancer.Lab Invest. 1999; 79: 271-280
- Immunohistochemical detection of DNA topoisomerase II alpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.Br J Cancer. 1998; 77: 1469-1473
- Mechanism of technetium 99m sestamibi parathyroid imaging and the possible role of P-glycoprotein.Surgery. 1996; 120: 1039-1045
- P-glycoprotein is expressed in parathyroid epithelium and is regulated by calcium.Calcified Tissue Int. 1995; 56: 170-174
Article info
Publication history
Accepted:
May 31,
2002
Footnotes
*Supported in part by grants from National Science Council (NSC 90-2314-B-039-026, 89-2320-B-075A-001-M08, 88-2314-B-075A-006), Taiwan.
**Reprint requests: Hurng-Sheng Wu, MD, Department of Surgery, Show-Chwan Memorial Hospital, No 542, Sec 1, Chung-Shang Rd, Changhua, 50005, Taiwan.
Identification
Copyright
© 2002 Mosby, Inc. Published by Elsevier Inc. All rights reserved.
